Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-Center, Phase II, Open Label, Single-Arm Trial of Durvalumab and Epacadostat in Patients With Unresectable, Recurrent, and Metastatic EBV+ NPC

NCT04231864 is registered in ClinicalTrials.gov with Alain Algazi as lead sponsor.

NCT NCT04231864
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04231864 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-Center, Phase II, Open Label, Single-Arm Trial of Durvalumab and Epacadostat in Patients With Unresectable, Recurrent, and Metastatic EBV+ NPC
Lead sponsor
Alain Algazi
Phase
Phase 2
Overall status
Withdrawn
Start date
December 1, 2020
Completion date
April 1, 2024
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

epstein-barr virus positive, metastatic nasopharyngeal carcinoma, recurrent nasopharyngeal carcinoma, stage iii nasopharyngeal carcinoma, stage iv nasopharyngeal carcinoma, stage iva nasopharyngeal carcinoma, stage ivb nasopharyngeal carcinoma